UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ ...

Exhibit 99.1 Axonics Reports First Quarter 2024 Financial Results IRVINE, Calif. – April 30, 2024 – Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024. "Our commercial team continued to execute at a high level in the first quarter, generating revenue growth of 29% year over year across our portfolio of incontine ...

Axonics, Inc. (AXNX) recently achieved a milestone with the CE Mark approval of its fourth-generation rechargeable Sacral Neuromodulation (SNM) system, the R20. This groundbreaking device is set to redefine the treatment landscape for bladder and bowel dysfunction, offering new hope to patients grappling with these challenging conditions.The R20 system is engineered for longevity and convenience, boasting a functional lifespan of at least 20 years within the body. This remarkable durability reduces the freq ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once every 6 to ...

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 116.67%. A quarter ago, it was expected that this medical technology company would post a loss of $0.05 per share when it actually produced earnings of $0.08, delivering a surprise of 260%.Over the ...

| --- | --- | |-------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------| | Commission File Number: _________________________________________________________________ | 001-38721 | | Axonics, (Exact name of registrant as specified _________________________________________________________________ | Inc. in its charter) | | Delaware incorporation or organization) (State or other jurisd ...

A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance. In fact, efficiency level, which measures a company’s capability to transform available input into output, is often considered an important parameter for gauging its potential to make profits.However, at times it becomes difficult to measure the efficiency level of a company. This is why one must consider popular efficiency ratios while selecting stocks.The ...

Shares of Axonics (AXNX 20.48%) were up 20.5% on Monday after the urology company agreed to be acquired by Boston Scientific (BSX 0.45%). Boston Scientific shares were also up around half a percent on the news today.A win-win deal for Axonics and Boston ScientificMore specifically, Axonics agreed to be acquired by Boston Scientific for $71 per share in cash, good for an equity value of $3.7 billion and (excluding Axonics' net cash and short-term investments) an enterprise value of $3.4 billion. Axonics shar ...

Axonics, Inc. (NASDAQ:AXNX) Q3 2023 Earnings Conference Call October 30, 2023 4:30 PM ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Officer Kari Keese - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Securities Richard Newitter - Truist Securities Adam Maeder - Piper Sandler Mike Polark - Wolfe Research Mike Matson - Needham & Company David Resc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______ ...